Single-use Bioprocessing System Market Analysis, Size, and Forecast 2026-2030:
North America (US, Canada, and Mexico), Europe (Germany, UK, and France), Asia (China, India, and Japan), South America (Brazil, Argentina, and Colombia), Middle East and Africa (Saudi Arabia, UAE, and Turkey), Rest of World (ROW)

Single-Use Bioprocessing System Market Size 2026-2030

The single-use bioprocessing system market size is valued to increase by USD 24.36 billion, at a CAGR of 21.4% from 2025 to 2030. Rising biologics demand and flexible manufacturing will drive the single-use bioprocessing system market.

Major Market Trends & Insights

• North America dominated the market and accounted for a 35.6% growth during the forecast period.
• By Application - mAb production segment was valued at USD 4.37 billion in 2024
• By Product - Bags and mixers segment accounted for the largest market revenue share in 2024

Market Size & Forecast

• Market Opportunities: USD 32.18 billion
• Market Future Opportunities: USD 24.36 billion
• CAGR from 2025 to 2030 : 21.4%

Market Summary

• The Single-use Bioprocessing System Market is undergoing a rapid structural transition as pharmaceutical developers abandon rigid stainless-steel infrastructure in favor of modular disposable architectures. In modern contract manufacturing, operators frequently pivot between distinct therapeutic molecules within the same cleanroom, relying on pre-sterilized assemblies and disposable bioreactors to guarantee cross-contamination prevention.
• This strategic shift has enabled facilities to achieve a 40% reduction in utility expenditures by eliminating water-intensive cleaning validation processes. The imperative for flexible production capacity serves as a primary driver, compelling biomanufacturers to scale up targeted therapies and vaccines without enduring decade-long facility construction timelines.
• However, this transition is constrained by formidable solid waste mitigation challenges, as the extensive reliance on multilayer polymer films generates massive volumes of biohazardous synthetic debris. Navigating stringent regulatory compliance standards for extractables and leachables testing further complicates procurement strategies. Ultimately, balancing rapid facility deployment against escalating ecological liabilities defines the current operational reality for major biopharmaceutical enterprises.

What will be the Size of the Single-Use Bioprocessing System Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Get Free Sample

How is the Single-Use Bioprocessing System Market Segmented?

The single-use bioprocessing system industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.

By Application Insights

The mab production segment is estimated to witness significant growth during the forecast period.

Get Free Sample

The mAb production segment was valued at USD 4.37 billion in 2024 and showed a gradual increase during the forecast period.

Get Free Sample

Regional Analysis

North America is estimated to contribute 35.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Single-Use Bioprocessing System Market Demand is Rising in North America Get Free Sample

The Single-use Bioprocessing System Market exhibits distinct adoption patterns, with North America leading technological integration while APAC demonstrates the most aggressive capacity expansion.

Biomanufacturers in North America utilize advanced disposable bioreactors and inline optical sensors to achieve a 30% reduction in process development timelines, prioritizing high-density cell cultivation for complex biologics.

Conversely, the APAC region leverages sterile fluid transfer systems to establish new multi-product facilities, accelerating capital expenditure reduction by up to 45% compared to legacy steel plants.

This regional divergence highlights how mature markets focus on batch-to-batch consistency and supply chain resilience, whereas emerging hubs prioritize rapid facility deployment.

Through pre-sterilized assemblies, both geographies successfully optimize their manufacturing footprints, although APAC facilities report a 20% faster turnaround time optimization due to the immediate deployment of greenfield disposable infrastructure.

Market Dynamics

Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

• The integration of flexible contract manufacturing bioprocessing platforms represents a critical evolution in how biopharmaceutical organizations manage unpredictable clinical demand. Unlike traditional rigid stainless-steel setups, the utilization of single-use bioreactors for monoclonal antibodies allows facility operators to transition between different therapeutic product lines with a 40% faster changeover rate.
• This operational fluidity is heavily dependent on maintaining sterile fluid transfer in biomanufacturing, which neutralizes the threat of batch carryover and protects high-value biologic substances.
• As continuous processing paradigms gain traction, the industry is increasingly relying on continuous bioprocessing with disposable sensors to monitor critical quality attributes in real-time, eliminating the need for manual sampling and reducing labor overhead by approximately 25%. However, substituting permanent piping with polymer-based consumables introduces distinct compliance challenges.
• Quality assurance teams must navigate rigorous extractables and leachables regulatory testing to verify that synthetic contact materials do not compromise drug efficacy or patient safety. By successfully addressing these material compatibility concerns, biomanufacturers can leverage the full spectrum of disposable technologies to optimize their supply chain resilience.
• This strategic approach ensures that targeted therapies reach commercial scale without the prohibitive capital expenditures traditionally associated with large-scale biopharmaceutical infrastructure.

What are the key market drivers leading to the rise in the adoption of Single-Use Bioprocessing System Industry?

• Rising biologics demand and the imperative for flexible manufacturing infrastructure function as primary catalysts accelerating the adoption of disposable bioprocessing platforms.

• The urgent necessity for rapid biopharmaceutical process scaling drives the aggressive expansion of the Single-use Bioprocessing System Market. Because fixed stainless-steel facilities require years of engineering and validation, manufacturers are pivoting to continuous biomanufacturing using disposable formats.
• The complete clean-in-place elimination and steam-in-place elimination drastically lower facility maintenance burdens, allowing operators to achieve a 45% reduction in annual water consumption and a 30% drop in energy expenditure.
• Leveraging biocompatible polymer films and gamma-irradiated components enables instantaneous production readiness, which is crucial for dynamic supply chains. Through integrated process analytical technology, facilities maintain strict environmental sustainability metrics while utilizing advanced depth filtration cassettes to streamline operations.
• This operational efficiency directly improves profit margins while accommodating volatile clinical demands.

What are the market trends shaping the Single-Use Bioprocessing System Industry?

• The expansion of outsourced biomanufacturing serves as a definitive trend reshaping operational strategies. Contract service providers increasingly rely on flexible production capacity to manage diverse therapeutic pipelines.

• The integration of automated closed-system architecture within the Single-use Bioprocessing System Market fundamentally alters how facilities manage high-value therapeutics. Because targeted treatments like viral vector manufacturing demand absolute sterility, operators are rapidly adopting aseptic connectors and pre-sterilized fluid pathways to guarantee cross-contamination prevention.
• This technological transition away from open-vessel handling has improved downstream purification efficiency by 28%, significantly boosting the yield of delicate biologic products. Furthermore, the implementation of scalable upstream processing allows contract organizations to transition from clinical batches to commercial output with a 40% reduction in setup downtime.
• As recombinant protein synthesis grows more complex, the reliance on validated disposable flow paths ensures that the vaccine formulation process remains uncontaminated, enabling biomanufacturers to deliver vital therapies faster and with greater consistency.

What challenges does the Single-Use Bioprocessing System Industry face during its growth?

• Environmental sustainability mandates and the complexities of solid waste management present formidable operational hurdles that constrain the unmitigated expansion of disposable bioprocessing technologies.

• Escalating material compliance hurdles and ecological liabilities severely constrain the unmitigated adoption of the Single-use Bioprocessing System Market. Because multi-product facilities consume vast quantities of synthetic polymers during mammalian cell culture, operations generate massive biohazardous waste streams, triggering urgent solid waste mitigation requirements. This reliance on consumables has increased recurring procurement costs by 25% compared to legacy reusable systems.
• Furthermore, integrating single-use chromatography columns demands rigorous quality-by-design implementation to identify potential chemical leachables. Implementing continuous real-time parameter monitoring across modular cleanroom integration setups helps stabilize production, but validation delays can reduce overall operational efficiency by up to 15% during the initial tech transfer phases.
• Securing patient safety through stringent bioburden reduction while navigating clinical trial manufacturing protocols remains a formidable balancing act for major biopharmaceutical enterprises.

Exclusive Technavio Analysis on Customer Landscape

The single-use bioprocessing system market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the single-use bioprocessing system market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape of Single-Use Bioprocessing System Industry

Competitive Landscape

Companies are implementing various strategies, such as strategic alliances, single-use bioprocessing system market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

ABEC Inc. - This unified segment delivers scalable disposable bioreactor platforms and advanced mixing solutions that accelerate setup times and eliminate elaborate cleaning protocols for seamless biopharmaceutical manufacturing integration.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• ABEC Inc.
• Adolf Kuhner AG
• Cellexus Ltd
• CerCell AS
• Compagnie de Saint Gobain SA
• Corning Inc.
• Cytiva
• Distek Inc.
• Entegris Inc.
• Eppendorf SE
• Getinge AB
• Infors AG
• Meissner Filtration Products
• Merck KGaA
• OmniBRx Biotechnologies Pvt Ltd
• Parker Hannifin Corp.
• PBS Biotech Inc.
• Repligen Corp.
• Sartorius AG
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Single-use bioprocessing system market

• In the Life Sciences Tools and Services industry, the shift toward continuous biomanufacturing protocols has increased the demand for closed-system fluid pathways, directly impacting Single-use Bioprocessing System demand by requiring advanced aseptic connectors and inline optical sensors integration.
• Stringent regulatory updates regarding cross-contamination prevention in multi-product facilities have compelled biopharmaceutical developers to eliminate shared stainless-steel infrastructure, accelerating the adoption of pre-sterilized assemblies to maintain compliance.
• The rapid expansion of decentralized viral vector manufacturing for personalized medicine production has forced contract developers to adopt modular cleanroom architectures, which pull high volumes of flexible mixing bags and depth filtration cassettes to ensure operational agility.
• Heightened environmental sustainability mandates focusing on water conservation have penalized traditional clean-in-place operations, thereby driving the transition toward biocompatible polymer films and gamma-irradiated components that drastically reduce facility water consumption and utility overhead.

Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Single-Use Bioprocessing System Market insights. See full methodology.

Request Free Sample

Research Analyst Overview

• The Single-use Bioprocessing System Market continues to evolve as pharmaceutical executives increasingly prioritize modular cleanroom integration over traditional facility construction. This strategic pivot allows boardroom decision-makers to defer massive capital expenditures, aligning budget allocations with clinical trial success rates rather than speculative infrastructure build-outs.
• By adopting single-use chromatography columns and disposable bioreactors, manufacturers have successfully achieved a 35% reduction in overall processing time, accelerating the journey from process development to commercial supply. The transition is particularly evident in mammalian cell culture operations, where the necessity for bioburden reduction dictates the use of closed, pre-sterilized assemblies.
• Furthermore, advanced inline optical sensors provide the real-time data fidelity required to maintain strict regulatory compliance without manual intervention. As continuous biomanufacturing protocols mature, the reliance on high-performance depth filtration cassettes and biocompatible polymer films becomes essential for safeguarding therapeutic yield.
• Ultimately, this structural shift empowers biopharmaceutical developers to maintain unparalleled operational agility while mitigating the financial risks inherent to complex recombinant protein synthesis.

What are the Key Data Covered in this Single-Use Bioprocessing System Market Research and Growth Report?

• What is the expected growth of the Single-Use Bioprocessing System Market between 2026 and 2030?

  • USD 24.36 billion, at a CAGR of 21.4%

• What segmentation does the market report cover?

  • The report is segmented by Application (mAb production, Vaccine production, Plant cell cultivation, PSCTs, and Others), Product (Bags and mixers, Bioreactors and fermenters, Filtration devices, Bioprocess containers, and Others), End-user (Pharmaceutical companies, CROs and CMOs, Biotechnology companies, and Academic) and Geography (North America, Europe, Asia, Rest of World (ROW))

• Which regions are analyzed in the report?

  • North America, Europe, Asia and Rest of World (ROW)

• What are the key growth drivers and market challenges?

  • Rising biologics demand and flexible manufacturing, Environmental sustainability and solid waste management hurdles

• Who are the major players in the Single-Use Bioprocessing System Market?

  • ABEC Inc., Adolf Kuhner AG, Cellexus Ltd, CerCell AS, Compagnie de Saint Gobain SA, Corning Inc., Cytiva, Distek Inc., Entegris Inc., Eppendorf SE, Getinge AB, Infors AG, Meissner Filtration Products, Merck KGaA, OmniBRx Biotechnologies Pvt Ltd, Parker Hannifin Corp., PBS Biotech Inc., Repligen Corp., Sartorius AG and Thermo Fisher Scientific Inc.

Market Research Insights

• The Single-use Bioprocessing System Market leverages closed-system architecture to fundamentally alter facility economics. By transitioning away from permanent infrastructure, biomanufacturers achieve a 35% reduction in overall capital expenditure reduction and a 50% improvement in turnaround time optimization between clinical batches. The widespread elimination of steam-in-place procedures slashes energy consumption by nearly 40%, directly aligning with corporate environmental sustainability metrics.
• Furthermore, ensuring batch-to-batch consistency through fluid management automation allows multi-product facilities to maintain high throughput without compromising therapeutic integrity. These measurable efficiency gains demonstrate how disposable platforms provide critical supply chain resilience for modern biological production.

We can help! Our analysts can customize this single-use bioprocessing system market research report to meet your requirements.

Get in touch